C-Reactive Protein (CRP) in Obese Diabetic Women

Phase 4 Completed 100 enrolled AstraZeneca Mexican National Institute of Public Health · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.

Timeline

Start: 2005-10
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosuvastatin	Small molecule	—	—

C-Reactive Protein (CRP) in Obese Diabetic Women

Summary

Timeline

Drugs

Indications